Lucid Diagnostics Announces Positive Data from its ESOGUARD BE-1 Prospective, International, Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing in a Screening Population

July 2, 2024

https://www.prnewswire.com/news-releases/lucid-diagnostics-announces-positive-data-from-its-esoguard-be-1-prospective-international-multicenter-clinical-validation-study-of-esoguard-esophageal-precancer-testing-in-a-screening-population-302187721.html

Prospective screening study demonstrates excellent EsoGuard sensitivity of 87.5% and negative predictive value (NPV) of 98.6%

Previously announced positive data from a separate prospective VA screening study also accepted for peer-reviewed publication

Read more at prnewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.